Who is sponsoring NCT05036304?

NCT05036304 is sponsored by University of British Columbia.

What drugs are being tested in NCT05036304?

Interventions in NCT05036304: Aerobic Exercise Indoors, Aerobic Exercise Outdoors.

What condition does NCT05036304 study?

NCT05036304 studies Mild Cognitive Impairment, Aging.

Is NCT05036304 still recruiting?

NCT05036304 is currently completed. Last updated 29 January 2024.

Last reviewed 2024-01-29 · How we verify

NCT05036304: SAGE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Supporting Aging Through Green Exercise (SAGE)

Completed NA Last updated 29 January 2024

What this trial tests

NA trial testing Aerobic Exercise Indoors in Mild Cognitive Impairment in 72 participants. Completed in 27 November 2023.

Timeline

19 January 2022

Primary endpoint
10 July 2023

27 November 2023

Quick facts

Lead sponsor	University of British Columbia
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	72
Start date	19 January 2022
Primary completion	10 July 2023
Estimated completion	27 November 2023
Sites	1 location across Canada

Drugs / interventions tested

Aerobic Exercise Indoors
Aerobic Exercise Outdoors

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Aging — all drugs for Aging →

Sponsor

University of British Columbia

Who can join

Adults 65 to 80, any sex, with Mild Cognitive Impairment or Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aerobic exercise is an evidence-based approach to mitigate cognitive decline in older adults with mild cognitive impairment (MCI). Emerging evidence suggests that the cognitive benefits of exercise may be enhanced when performed in outdoor, natural settings, as compared to indoor or built settings. Thus, the investigators aim to compare the effects of outdoor versus indoor walking programs on cognitive function among older adults with MCI. Secondary outcomes are motor function, emotional well-being, health-related behaviours, and quality of life. Participants will be randomly assigned to a 12--week, 3x/week program of either outdoor walking on forest trails or indoor walking on a treadmill. A 3-month followup will also be completed after trial completion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other University of British Columbia trials

Trials by the same sponsor.

NCT07340970 — Sensory Stimuli During Cesarean Delivery · not yet recruiting
NCT07481201 — Phenylalanine Requirements in the Menstrual Phases · NA · not yet recruiting
NCT07492095 — Leucine Requirements in School-Age Children · NA · not yet recruiting
NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05036304 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
Last refreshed: 29 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05036304.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing